Covance's competitors

Covance's competitors include MyoKardia, Threshold Pharmaceuticals, Shire and Biogen
Add company...
Covance
Covance, the drug development business of Laboratory Corporation of America Holdings (LabCorp), is the world's most comprehensive drug development company.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Threshold Pharmaceuticals
Threshold Pharmaceuticals is focused on the development of drugs targeting Tumor Hypoxia, a low oxygen condition found in solid tumors.
Shire
Shire is a specialty biopharmaceutical company.
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
Founding Date
Founding Date
1968
Founding Date
N/A
Founding Date
2001
Founding Date
1986
Founding Date
1978
Type
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Princeton, US HQ
Locations
South San Francisco, US HQ
Locations
South San Francisco, US HQ
Locations
Dublin, IE HQ
Buenos Aires, AR
Sydney, AU
Wien, AT
Bruxelles, BE
Chácara Santo Antonio (Zona Sul), BR
Sofia, BG
see more
Locations
Cambridge, US HQ
Employees
Employees
9,495
Employees
1024% increase
Employees
1512% decrease
Employees
23,0444% decrease
Employees
7,3001% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
1.7 b
Valuation ($)
191.2 m
Valuation ($)
50.3 b
Valuation ($)
60.4 b
Facebook likes
Facebook likes
3.8 k
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
3.1 k
Twitter followers
Twitter followers
8 k
Twitter followers
387
Twitter followers
N/A
Twitter followers
6.2 k
Twitter followers
19.4 k

Financial

Revenue (est.)
Revenue (est.)
$2.6b (FY, 2013)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$15.2b (FY, 2017)
Revenue (est.)
$11.4b (FY, 2016)
Net income
Net income
$179.2m (FY, 2013)
Net income
($46m) (FY, 2017)
Net income
($24.1m) (FY, 2016)
Net income
$4.3b (FY, 2017)
Net income
$3.7b (FY, 2016)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
7 (FY, 2017)
Phase I Trials Products
4 (FY, 2016)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2017)
Phase II Trials Products
10 (FY, 2016)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
15 (FY, 2017)
Phase III Trials Products
2 (FY, 2016)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 49.3m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Threshold Pharmaceuticals
HQ
South San Francisco, US
Employees
15↓ 12% decrease

Threshold Pharmaceuticals is focused on the development of drugs targeting Tumor Hypoxia, a low oxygen condition found in solid tumors.

View company
Shire
HQ
Dublin, IE
Employees
23,044↓ 4% decrease

Shire is a specialty biopharmaceutical company.

View company
Biogen
HQ
Cambridge, US
Employees
7,300↓ 1% decrease

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company